Sort   by:  
 Page size 
UnknownIdarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Not available
S-EPMC6778960 | biostudies-literature
UnknownThe emerging role of immune checkpoint based approaches in AML and MDS.
Not available
S-EPMC5872841 | biostudies-literature
UnknownICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype.
Not available
S-EPMC10959121 | biostudies-literature
UnknownEfficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
Not available
S-EPMC6397669 | biostudies-literature
UnknownAssociation of social vulnerability and depression incidence post intracerebral haemorrhage: a cohort study.
Not available
S-EPMC11667396 | biostudies-literature
UnknownA Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.
Not available
S-EPMC11216872 | biostudies-literature
UnknownCombined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naive metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment.
Not available
S-EPMC8524287 | biostudies-literature
UnknownMacrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade.
Not available
S-EPMC12776307 | biostudies-literature
UnknownRole of miRNAs in immune responses and immunotherapy in cancer.
Not available
S-EPMC6368474 | biostudies-literature
UnknownNivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.
Not available
S-EPMC5809128 | biostudies-literature
Sort   by:  
 Page size